To examine the benefits of adding salmeterol compared with increasing dose of inhaled corticosteroids in symptomatic asthma.
How were the studies combined?
Pooled weighted mean differences were calculated with 95% confidence intervals (CIs) using both fixed-effect and random-effects models. Studies were weighted according to inverse study variance.
A funnel plot was used to test for publication bias.
How were differences between studies investigated?
Heterogeneity was formally tested and p-values reported.
Results of the review
Nine RCTs were included in the review with 3,685 participants.
The number needed to treat (NNT) was approximately 40.
Compared with response to increased steroids, in patients receiving salmeterol, morning peak expiratory flow was greater at three months (difference 22.4 (95% CI: 15.0, 30.0) litre/min, P < 0.001) and six months (27.7 (95% CI: 19.0, 36.4) litre/min, P < 0.001). There was no statistically significant heterogeneity.
Forced expiratory volume in one second (FEV1) was also increased at three months (0.10 (95% CI: 0.04, 0.16) litres, P < 0.001) and six months (0.08 (95% CI: 0.020, 014) litres, P < 0.01). There was no statistically significant heterogeneity.
Mean percentage of days and nights without symptoms (three months: days, 12% (95% CI: 9%, 15%), nights, 5% (95% CI: 3%, 7%); six months: days, 15% (95% CI: 12%, 18%), nights, 5% (95% CI: 3%, 7%); all P < 0.001. There was no statistically significant heterogeneity.
Mean percentage of days and nights without need for rescue treatment (three months: days, 17% (95% CI: 14%, 20%), nights, 9% (95% CI: 7%,11%); six months: days, 20% (95% CI: 17%, 23%), nights, 8% (95% CI: 6%, 11%); all P < 0.001.
Fewer patients experienced any exacerbation with salmeterol (difference 2.73% (95% CI: 0.43%, 5.04%), P = 0.02), and the proportion of patients with moderate or severe exacerbations was also lower (2.42% (95% CI: 0.24%, 4.60%), P = 0.03).
Authors' conclusions
The authors state that addition of salmeterol in symptomatic patients, aged 12 years and over, on low to moderate doses of inhaled steroid gives improved lung function and increased number of days and nights without symptoms or need for rescue treatment with no increase in exacerbations of any severity.
CRD commentary
This review was well reported. The authors have clearly stated the research question and inclusion and exclusion criteria. The literature search was reasonably thorough with no language restrictions, although searches for unpublished and grey literature were not mentioned.
The quality of the included studies was not formally assessed but the authors did state that the included studies met the company-wide minimum quality standards. The authors have reported how the articles were selected, and who performed the selection, although this was done by only one person. The validity assessment was managed by one of the authors, while the data extraction was done by two of the researchers and checked by a third.
The data extraction is reported in tables and discussed in the text of the review. The studies were combined in a statistical analysis, however, the authors state that the results of the analysis may not be generalisable in clinical practice because of limitations in the way study participants were chosen for the individual studies. Six studies used a requirement for entry of a demonstrable, clinically relevant, response to beta-agonist. In the other three studies airway
